Integrating genetic and telomere assessments into clinical care helps physicians refine diagnoses and adjust treatment plans for patients with pulmonary fibrosis.
RT’s Three Key Takeaways:
- Clinical Care Impact: A Mayo Clinic study of 66 patients found that combining genetic testing with telomere length measurement changed clinical management for more than half of the participants.
- Identification of Genetic Variants: Researchers identified disease-causing genetic variants in nearly one in five study participants, helping to uncover the underlying drivers of progressive lung scarring.
- Family Risk Assessment: Genetic and telomere insights allow clinicians to identify at-risk family members, facilitating earlier screening, counseling, and specialized healthcare through new clinical models.
Mayo Clinic researchers found that integrating telomere length evaluation and genetic testing into pulmonary care significantly alters how physicians diagnose and treat pulmonary fibrosis, according to a study published in Mayo Clinic Proceedings.
Telomeres are protective caps at the ends of chromosomes that naturally shorten with age. In some inherited conditions, these caps become unusually short, a factor linked to certain forms of pulmonary fibrosis. This group of diseases causes progressive scarring in the lungs, making breathing increasingly difficult for patients.
In a study of 66 patients, nearly one in five participants had a disease-causing genetic variant. The integration of testing changed clinical care in more than half of the patients involved in the research.
“These diseases are often difficult to diagnose, and patients may be treated based on incomplete or unclear underlying causes,” said Kathryn del Valle, a Mayo Clinic pulmonologist and lead author of the study.
To address diagnostic challenges, researchers paired genetic testing with telomere length measurement to uncover hidden drivers of the disease and guide management decisions.
“This work demonstrates a practical, scalable way to incorporate genetic and telomere assessment into clinical care for patients with fibrotic interstitial lung disease,” said Eva Carmona, a Mayo Clinic pulmonologist and senior author.
The insights from testing led to changes in the evaluation of comorbidities, medication adjustments, referrals to specialized clinics, and earlier consideration of lung transplant. This information also helps clinicians avoid treatments and procedures that may be ineffective or harmful for patients with specific genetic or telomere-related conditions.
“Genetic and telomere testing may help elucidate why disease is occurring, guide management decisions and identify family members who may be at risk,” said Carmona.
Beyond individual patient management, the findings have implications for families. Identifying a genetic cause helps flag relatives who may be at risk, allowing them to pursue earlier screening, genetic counseling, and testing.
Mayo Clinic plans to expand this model by launching a Familial Pulmonary Fibrosis Clinic to coordinate genetic testing, counseling, and care for patients and at-risk relatives.
